Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Astaxanthin has not been tested in clinical trials for ALS

Original source

AstaxanthinALSUntangled · 25 January 2023 (opens in a new tab)

Astaxanthin has theoretical mechanisms that could be relevant to amyotrophic lateral sclerosis (ALS), but it has not been tested in ALS-specific preclinical studies or clinical trials in people with ALS. A reported ALS reversal occurred while one person was taking astaxanthin alongside several other therapies, so the association does not show that astaxanthin caused the improvement.

Why this matters

People with ALS do not have clinical evidence that astaxanthin treats the disease. Further studies in ALS models and clinical trials would be needed to assess whether it is effective.

Limitations and context

This assessment is an independent expert review, not a clinical trial. The evidence described is limited to theoretical mechanisms and one reported case involving multiple therapies; astaxanthin’s effectiveness in ALS remains unknown.

Summarised by Compass 9 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?